U.S. FDA Approves Label Update for Beremagene Geperpavec-svdt (Vyjuvek, Krystal Biotech, Inc.) in DEB
The U.S. Food and Drug Administration (FDA) approved a label update for beremagene geperpavec-svdt (Vyjuvek, Krystal Biotech, Inc.) that expands the eligible patient population to include dystrophic epidermolysis bullosa (DEB) patients from birth and provides patients full flexibility with respect to application and managing wound dressings.